NASDAQ:SXTP 60 Degrees Pharmaceuticals (SXTP) Stock Price, News & Analysis $0.19 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.18▼$0.2050-Day Range$0.18▼$0.3552-Week Range$0.17▼$2.29Volume3.41 million shsAverage Volume2.38 million shsMarket Capitalization$2.30 millionP/E RatioN/ADividend YieldN/APrice Target$2.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get 60 Degrees Pharmaceuticals alerts: Email Address 60 Degrees Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,175.2% Upside$2.40 Price TargetShort InterestBearish7.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.56) to ($0.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.52 out of 5 stars 3.3 Analyst's Opinion Consensus Rating60 Degrees Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst Coverage60 Degrees Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about 60 Degrees Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.86% of the float of 60 Degrees Pharmaceuticals has been sold short.Short Interest Ratio / Days to Cover60 Degrees Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 60 Degrees Pharmaceuticals has recently increased by 166.35%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yield60 Degrees Pharmaceuticals does not currently pay a dividend.Dividend Growth60 Degrees Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SXTP. Previous Next 2.4 News and Social Media Coverage News Sentiment60 Degrees Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for 60 Degrees Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SXTP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added 60 Degrees Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 60 Degrees Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.27% of the stock of 60 Degrees Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.96% of the stock of 60 Degrees Pharmaceuticals is held by institutions.Read more about 60 Degrees Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for 60 Degrees Pharmaceuticals are expected to grow in the coming year, from ($0.56) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 60 Degrees Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 60 Degrees Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about 60 Degrees Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About 60 Degrees Pharmaceuticals Stock (NASDAQ:SXTP)60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.Read More SXTP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SXTP Stock News HeadlinesJuly 26 at 7:18 AM | americanbankingnews.com60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Sees Large Growth in Short InterestJuly 25 at 8:16 PM | finanznachrichten.deSixty Degrees Pharmaceuticals: 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA Supply Chain Upgrade SupportJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 25 at 8:16 PM | finance.yahoo.com60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade SupportJuly 20, 2024 | msn.comDow Tumbles Over 100 Points; American Express Earnings Beat ViewsJuly 20, 2024 | finance.yahoo.com(XS2531438351.SG)July 20, 2024 | markets.businessinsider.com60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis StudyJuly 20, 2024 | msn.comWhy Are 60 Degrees Pharmaceuticals Shares Up By 50% Today?July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 19, 2024 | globenewswire.com60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis StudyJuly 19, 2024 | investorplace.comWhy Is 60 Degrees (SXTP) Stock Up 56% Today?July 9, 2024 | globenewswire.com60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior TreatmentJune 27, 2024 | globenewswire.comFirst Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its KindMay 30, 2024 | globenewswire.comEnrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its KindMay 20, 2024 | globenewswire.com60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine StudyMay 16, 2024 | markets.businessinsider.comBalancing Act: Hold Rating Amid Positive Earnings and Upcoming Babesiosis Trial UncertaintiesMay 15, 2024 | globenewswire.com60 Degrees Pharmaceuticals Announces First Quarter 2024 ResultsMay 8, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesSee More Headlines Receive SXTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 60 Degrees Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SXTP CUSIPN/A CIK1946563 Web60degreespharma.com Phone202-327-5422FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$2.40 High Stock Price Target$2.40 Low Stock Price Target$2.40 Potential Upside/Downside+1,175.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,770,000.00 Net MarginsN/A Pretax Margin-848.39% Return on EquityN/A Return on Assets-78.95% Debt Debt-to-Equity RatioN/A Current Ratio7.16 Quick Ratio6.77 Sales & Book Value Annual Sales$250,000.00 Price / Sales9.19 Cash FlowN/A Price / Cash FlowN/A Book Value($0.87) per share Price / Book-0.22Miscellaneous Outstanding Shares12,210,000Free Float10,952,000Market Cap$2.30 million OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Geoffrey Stuart Dow (Age 50)Chairman, CEO & President Comp: $125.56kMr. Tyrone Miller (Age 49)CFO & Treasurer Comp: $135.63kDr. Bryan Smith (Age 58)Chief Medical Officer Ms. Kristen Landon (Age 57)Chief Commercial Officer Ms. Jennifer HerzDirectorKey CompetitorsAeterna ZentarisNASDAQ:AEZSAgile TherapeuticsNASDAQ:AGRXPieris PharmaceuticalsNASDAQ:PIRSMoleculin BiotechNASDAQ:MBRXABVC BioPharmaNASDAQ:ABVCView All CompetitorsInstitutional OwnershipCentral Bank & Trust Co.Sold 101,000 shares on 7/19/2024Ownership: 1.368%View All Institutional Transactions SXTP Stock Analysis - Frequently Asked Questions How have SXTP shares performed this year? 60 Degrees Pharmaceuticals' stock was trading at $1.02 at the start of the year. Since then, SXTP stock has decreased by 81.5% and is now trading at $0.1882. View the best growth stocks for 2024 here. How were 60 Degrees Pharmaceuticals' earnings last quarter? 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) released its quarterly earnings results on Wednesday, May, 15th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.19. The business had revenue of $0.08 million for the quarter. When did 60 Degrees Pharmaceuticals IPO? 60 Degrees Pharmaceuticals (SXTP) raised $7 million in an initial public offering on Wednesday, July 12th 2023. The company issued 1,400,000 shares at $5.30 per share. WallachBeth Capital LLC acted as the underwriter for the IPO. Who are 60 Degrees Pharmaceuticals' major shareholders? 60 Degrees Pharmaceuticals' top institutional shareholders include Central Bank & Trust Co. (1.37%). How do I buy shares of 60 Degrees Pharmaceuticals? Shares of SXTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SXTP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.